16. Other items or information:

December 3, 2001

Date of Deposit

Form PTO-1390-MOD U. S. Department of Commerce Patent and Trademark Office ATTORNEY'S DOCKET NUMBER (REV 10-96) 4-30970A U.S. APPLICATION NO. (If known, see 37 CFR 1.5) TRANSMITTAL LETTER TO THE UNITED STATES **DESIGNATED/ELECTED OFFICE (DO/EO/US)** 10/009008 CONCERNING A FILING UNDER 35 U.S.C. 371 INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED PCT/EP00/05058 2 June 2000 (02.06.00) 4 June 1999 (04.06.99) TITLE OF INVENTION **BETA2-ADRENOCEPTOR AGONISTS** APPLICANT(S) FOR DO/EO/US CUENOUD ET AL. Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay 3. examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. A copy of the International Application as filed (35 U.S.C. 371(c)(2)) 5. is transmitted herewith (required only if not transmitted by the International Bureau). has been transmitted by the International Bureau. (See Form PCT/IB/308) is not required, as the application was filed in the United States Receiving Office (RO/US). A translation of the International Application into English (35 U.S.C. 371(c)(2)). Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C.371(c)(3)). are transmitted herewith (required only if not transmitted by the International Bureau). have been transmitted by the International Bureau. have not been made; however, the time limit for making such amendments has NOT expired. have not been made and will not be made. A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)). An unexecuted Declaration and Power of Attorney (original or copy) (35 U.S.C. 371(c)(4)). A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11. to 16. below concern document(s) or information included. 11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment. 14. Bib Data Sheet. 15. A change of power of attorney and/or address letter.

 d PCT/PTO	_	DEC	200
A RNEY'S DOCKET NU	MBER		

IU/	0090	U 8 PCT	/EP00/05058		4	-30970A	OOKET NOMBER	
17. X The following fe							CALCULATION	S PTO USE ONLY
BASIC NATIONAL FEE (37 CFR 1.492(a) (1)-(5)):								
Search Report has been prepared by the EPO or JPO								
International preliminary examination fee paid to USPTO (37 CFR 1.482)								
\$710								
No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) \$740								
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$1,040								
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4)								
		ENTED A		010 55	5 A M OU		\$ 890	
ENTER APPROPRIATE BASIC FEE AMOUNT =						NI =		
Surcharge of \$130 for fu months from the earliest	claimed prio	rity date (37 C		30			\$	
CLAIMS		R FILED	NUMBER EXTRA		RATE	- 10		
Total claims Independent claims	21	- 20 =	1 0	X	<u>\$</u> \$	18 84	\$ 18 \$	
MULTIPLE DEPENDEN		_		+ ^	<u>Ψ</u> \$	280	\$	
MOZIN ZZ BZI ZNOZN			TOTAL OF ABO		•		\$ 908	
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be								
filed (Note 37 CFR 1.9,		. ,		,			\$	
					SUBTO	TAL =	\$ 908	
Processing fee of \$130 f the earliest claimed prior			anslation later than [] 20 [30 mont	hs from +	\$	
			ТО	TAL NA	TIONAL	FEE =	\$ 908	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +						\$	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	
			TOTAL	FEES E	NCLOS	ED =	\$ 908	
							Amount to be:	\$
							refunded	
· · · · · · · · · · · · · · · · · · ·							charged	\$
a. A check in the	amount of \$_		to cover the above	fees is er	nclosed.	•		
b. 🛛 Please charge fees. A duplica			34 in the name of No	vartis Corp	ooration in	the amou	nt of \$908 to cove	r the above
			charge any additiona of Novartis Corporati		ich may be	required,	or credit any ove	rpayment to
NOTE: Where an appro					been met,	a petitior	to revive (37 CF	FR 1.137(a) or
(b)) must be filed and granted to restore the application to pending status.								
Send all correspondence Customer No. 001095, v Thomas Hoxie	e to the addre	ess associated	with	(asor		Hesci	Wen.	12/3/01
Novartis Corporation /Carol A. Loeschorn						•	_, 0,07	
Patent and Trademark Dept. Attorney for Applicants For No. 25 500								
564 Morris Avenue , Reg. No. 35,590 Summit, NJ 07901-1027 (908) 522-6932								
l			,	,				